Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution

Core Viewpoint - Inspira Technologies has announced a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement (SEPA) to enhance its financial flexibility and support its strategic initiatives [1][4][7]. Group 1: Registered Direct Offering - The company will issue and sell 1,565,217 ordinary shares at a price of $1.15 per share, generating gross proceeds of approximately $1.8 million [2][9]. - The offering is expected to close on or about December 16, 2025, pending customary closing conditions [2]. Group 2: Standby Equity Purchase Agreement (SEPA) - The SEPA allows the company to sell up to $25 million of its ordinary shares over a 36-month period at its discretion, without any minimum purchase requirements [4][9]. - The company is not obligated to utilize this facility, providing it with opportunistic capital raising options as needed [4][9]. Group 3: Use of Proceeds - The net proceeds from the registered direct offering and any future proceeds from the SEPA will be used for working capital and general corporate purposes, specifically to support the company's strategic roadmap and planned operations [6][9]. Group 4: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing intellectual property portfolio [8][10].